Diesel Exhaust Particles and Leukotriene Production

Allergic Rhinitis Clinical Trial

Official title:

Diesel Exhaust Particles and Leukotriene Production

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00915447
• Other study ID #: IRB # 07-10-025
• Secondary ID: FAU # 441329-ZC-
• Status: Withdrawn
• Start date: April 2008
• Est. completion date: April 11, 2013

Study information

• Verified date: January 2019
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to measure the effects of allergens and/or diesel exhaust particles in the nose to learn more about allergic responses in individuals with cat allergic rhinitis.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 11, 2013
• Est. primary completion date: April 11, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 18 to 65 years old.

2. Positive prick (epicutaneous) skin test to standardized cat with a wheal equal to or greater than 3 mm and with a surrounding flare.

3. Ability to give informed consent.

Exclusion Criteria:

1. Pregnancy or breast-feeding. (Pregnancy and the period during breast feeding can affect nasal congestion and be a confounder in this regard.)

2. Systemic corticosteroid use within the previous three months or anytime during the challenge protocol.

3. Topical nasal corticosteroid use within the past month or anytime during the challenge protocol.

4. Systemic antihistamines or decongestant use within past two weeks or anytime during the trial.

5. Chronic sinusitis or chronic non-allergic rhinitis.

6. Use of reserpine.

7. Cigarette smoking within the past year or during the challenge protocol

8. Use of topical nasal antihistamines, chromoglycolates (chromolyn, Cromlon®), decongestants or non-steroidal anti-inflammatory agents (NSIADS) within the preceding week or anytime during the challenge protocol.

9. Present or treatment within the past 10 years with allergy immunotherapy (injections).

10. Present or past treatment with anti-IgE therapy.

11. Any unusual exposure to air pollutants (e.g., working as a diesel mechanic) that, in the opinion of the investigators, might compromise the individual's ability to participate in the study.

12. Living arrangement where the subject has a cat dwelling within the subject's habitation.

13. Any serious heart, lung, neurological or kidney disease that in the opinion of the investigators would impair the individual's ability to participate in the study.

14. Use of asthma-required medications.

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic

Locations

Country	Name	City	State
United States	University of California, Los Angeles	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Los Angeles	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United States,